We are live on
!
Find out more
SCM
Squadron Capital Management Portfolio holdings
AUM
$322M
This Fund
S&P 500
This Quarter
Est. Return
+39.23%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$36.9M
(+16%)
Cap. Flow
+$14.1M
Cap. Flow
% of AUM
5.18%
Top 10 Holdings %
Top 10 Hldgs %
67.07%
Holding
52
New
19
Increased
8
Reduced
8
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
+$9.38M |
| 2 |
ANL
Adlai Nortye
ANL
|
+$8.46M |
| 3 |
Relmada Therapeutics
RLMD
|
+$8.4M |
| 4 |
Nektar Therapeutics
NKTR
|
+$7.12M |
| 5 |
Relay Therapeutics
RLAY
|
+$6.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MAZE
Maze Therapeutics
MAZE
|
+$10.3M |
| 2 |
TERN
Terns Pharmaceuticals
TERN
|
+$7.68M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$6.55M |
| 4 |
UPB
Upstream Bio Inc
UPB
|
+$6.26M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$4.73M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Context Therapeutics
CNTX
$48M
| $2.88M | 1.06% |
+1,100,000
| New | +$2.57M |
|
27
NextCure
NXTC
$37.6M
| $2.83M | 1.04% |
265,000
+28,034
| +12% | +$342K |
|
28
CALL
ArriVent BioPharma
AVBP
$1.37B
| $2.54M | 0.93% |
110,000
-228,000
| -67% | -$5.15M |
|
29
Sol-Gel Technologies
SLGL
$277M
| $2.46M | 0.9% |
+31,000
| New | +$2.24M |
|
30
Pasithea Therapeutics
KTTA
$16.1M
| $1.56M | 0.57% |
2,100,000
| – | – |
|
|
31
CALL
Relay Therapeutics
RLAY
$4.35B
| $1.49M | 0.55% |
+150,000
| New | +$1.34M |
|
32
Traws Pharma
TRAW
$8.7M
| $936K | 0.34% |
511,714
-201,826
| -28% | -$379K |
|
|
33
CALL
Zentalis Pharmaceuticals
ZNTL
$255M
| $936K | 0.34% |
+400,000
| New | +$1.03M |
|
34
TherapeuticsMD
TXMD
$24M
| $849K | 0.31% |
+420,421
| New | +$945K |
|
|
SPRB
35
Spruce Biosciences
SPRB
$151M
| $797K | 0.29% |
12,200
-57,800
| -83% | -$3.99M |
|
36
Werewolf Therapeutics
HOWL
$19.7M
| $469K | 0.17% |
+563,535
| New | +$386K |
|
|
NEUP
37
Neuphoria Therapeutics
NEUP
$20.9M
| $312K | 0.11% |
+76,728
| New | +$324K |
|
38
Avalo Therapeutics
AVTX
$1.05B
| – | – |
-130,000
| Closed | -$2.36M |
|
|
BLTE
39
Belite Bio
BLTE
$6.53B
| – | – |
-26,000
| Closed | -$4.16M |
|
|
CMPS
40
Compass Pathways
CMPS
$1.86B
| – | – |
-388,287
| Closed | -$2.68M |
|
|
HELP
41
Cybin Inc
HELP
$743M
| – | – |
-525,000
| Closed | -$4.29M |
|
|
DBVT
42
DBV Technologies
DBVT
$881M
| – | – |
-240,000
| Closed | -$4.6M |
|
43
CALL
Intellia Therapeutics
NTLA
$1.67B
| – | – |
-81,000
| Closed | -$728K |
|
|
44
Tarsus Pharmaceuticals
TARS
$3.04B
| – | – |
-80,000
| Closed | -$6.55M |
|
|
TERN
45
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-190,000
| Closed | -$7.68M |
|
46
CALL
Vera Therapeutics
VERA
$2.28B
| – | – |
-60,000
| Closed | -$3.04M |
|
|
VTYX
47
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-410,000
| Closed | -$3.7M |
|
48
Wave Life Sciences
WVE
$1.07B
| – | – |
-175,000
| Closed | -$2.98M |
|
|
49
Xenon Pharmaceuticals
XENE
$6.03B
| – | – |
-105,551
| Closed | -$4.73M |
|
|
ZBIO
50
CALL
Zenas BioPharma
ZBIO
$1.86B
| – | – |
-36,000
| Closed | -$1.31M |
|
Similar funds
BCP
SFCM
ECH
BCM
KI
GWM
KC
HNH
Squadron Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Squadron Capital Management held 52 positions worth $273M, up 16% from $236M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Squadron Capital Management deployed $14.1M of net new capital in Q1 2026, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier.
On the sell side, the largest reduction was Maze Therapeutics, an estimated $10.3M trimmed.
- Squadron Capital Management's largest Q1 2026 buy was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M.
- Squadron Capital Management added most to Relmada Therapeutics in Q1 2026, an estimated $8.4M increase.
- Squadron Capital Management's biggest Q1 2026 reduction was Maze Therapeutics, cutting an estimated $10.3M.
- Squadron Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $7.68M.
- Squadron Capital Management's ten largest holdings make up 67% of its $273M portfolio in Q1 2026.
- Squadron Capital Management opened 19 new positions and closed 15 in Q1 2026.
- Squadron Capital Management's portfolio value rose 16% quarter-over-quarter to $273M.
Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.